Sentinel node mapping for early breast cancer patients using 99mTc-phytate: Single center experience on 165 patients

Iranian Journal of Nuclear Medicine

Volumn 20, Issue 2, 2012, Pages 25-29

  Kakhki, Vahid Reza Dabbagh ^a   Jangjoo, Ali ^b   Tavassoli, Alireza ^c   Asadi, Mahdi ^b   Sadri, Keyvan ^a   Masoom, Asiehsadat Fatahi ^c   Mehrabibahar, Mostafa ^b   Memar, Bahram ^d   Ansari, Mojtaba ^e   Sadeghi, Ramin ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Detection rate; Lymphoscintigraphy; Sentinel node; Tc 99m phytate

Indexed keywords

METHYLENE BLUE; PHYTATE TC 99M;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER PATIENT; DRUG EFFICACY; EARLY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPHATIC SYSTEM EXAMINATION; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; SENTINEL LYMPH NODE; SENTINEL NODE MAPPING;

EID: 84876205803     PISSN: 16812824     EISSN: 20082509     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wiatrek R, Kruper L. Sentinel lymph node biopsy n indications and controversies in breast cancer. Maturitas. 2011 May;69(1):7-10.
2. Kaviani A, Noveiry BB, Noaparast M. Sentinel lymph node biopsy in management of early breast cancer: Is it rational to omit blue dye injection? Surgery. 2012 Jul;152(1):140.
3. Iida S, Haga S, Yamashita K, Yanagihara K, Kurita T, Murakami R, Kumita S, Tsuchiya S, Furukawa K, Uchida E. Evaluation of sentinel lymph node biopsy in clinically node-negative breast cancer. J Nippon Med Sch. 2011;78(2):96-100.
4. Bekker J, Meijer S. The historical perspective of the sentinel lymph node concept. Ned Tijdschr Geneeskd. 2008 Jan 5;152(1):38-45.
5. Carmon M, Olsha O, Schecter WP, Raveh D, Reinus C, Hershko DD, Beller U, Golomb E. The "Sentinel Chain": a new concept for prediction of axillary node status in breast cancer patients. Breast Cancer Res Treat. 2006 Jun;97(3):323-8.
6. Sadeghi R, Zakavi SR, Forghani MN, Aryana K, Kakhki VR, Ayati NK, Shandiz FH, Ghavamnasiri MR, Keshtgar M. The efficacy of Tc-99m sestamibi for sentinel node mapping in breast carcinomas: comparison with Tc-99m antimony sulphide colloid. Nucl Med Rev Cent East Eur. 2010;13(1):1-4.
7. Sadeghi R, Forghani MN, Zakavi SR, Jangjoo A, Shabani GA, Kakhki VRD. The need for skin pen marking for sentinel lymph node biopsy: A comparative study. Iran J Nucl Med. 2008;16(2):23-7.
8. Eftekhari M, Beiki D, Fallahi B, Arabi M, Memari F, Gholamrezanezhad A, Esmaili J, Akhzari F, Fard- Esfahani A. Assessment the diagnostic accuracy of sentinel lymph nodes lymphoscintigraphy using Technetium-99m phytate in breast cancer. DARU. 2009;17(2):83-7.
9. Sadri K, Ayati NK, Shabani G, Zakavi SR, Sadeghi R. Sentinel node detection failure due to defective labeling and large particle size of Tc-99m antimony sulfide colloid. Iran J Nucl Med. 2011;19(1):6-11.
10. Aliakbarian M, Memar B, Jangjoo A, Zakavi SR, Reza Dabbagh Kakhki V, Aryana K, Forghani MN, Sadeghi R. Factors influencing the time of sentinel node visualization in breast cancer patients using intradermal injection of the radiotracer. Am J Surg. 2011 Aug;202(2):199-202.
11. Momennezhad M, Zakavi SR, Dabbagh Kakhki VR, Jangjoo A, Ghavamnasiri MR, Sadeghi R. Scatterogram: a method for outlining the body during lymphoscintigraphy without using external flood source. Radiol Oncol. 2011 Sep;45(3):184-8.
12. Eshima D, Fauconnier T, Eshima L, Thornback JR. Radiopharmaceuticals for lymphoscintigraphy: including dosimetry and radiation considerations. Semin Nucl Med. 2000 Jan;30(1):25-32.
13. Subramanian G, McAfee JG, Mehta A, Blair RJ, Thomas ED. Tc-99m stannous phytate: a new in vivo colloid for imaging the reticuloendothelial system. J Nucl Med. 1973;14:459.
14. Alavi A, Staum MM, Shesol BF, Bloch PH. Technetium-99m stannous phytate as an imaging agent for lymph nodes. J Nucl Med. 1978 Apr;19(4):422-6.
15. Tavares MG, Sapienza MT, Galeb NA Jr, Belfort FA, Costa RR, Osório CA, Góes JC, Endo IS, Soares J Jr, Lewin S, Marone MM. The use of 99mTc-phytate for sentinel node mapping in melanoma, breast cancer and vulvar cancer: a study of 100 cases. Eur J Nucl Med. 2001 Nov;28(11):1597-604.
16. Ege GN, Warbick A. Lymphoscintigraphy: a comparison of 99Tc(m) antimony sulphide colloid and 99Tc(m) stannous phytate. Br J Radiol. 1979 Feb;52(614):124-9.
17. Campbell J, Bellen JC, Baker RJ, Cook DJ. Technetium-99m calcium phytate-optimization of calcium content for liver and spleen scintigraphy: concise communication. J Nucl Med. 1981 Feb;22(2):157-60.
18. Sadeghi R, Forghani MN, Memar B, Rajabi Mashhadi MT, Dabbagh Kakhki VR, Abdollahi A, Zakavi SR. How long the lymphoscintigraphy imaging should be continued for sentinel lymph node mapping? Ann Nucl Med. 2009 Aug;23(6):507-10.
19. Takei H, Suemasu K, Kurosumi M, Ninomiya J, Horii Y, Inoue K, Tabei T. 99mTc-phytate is better than 99mTc-human serum albumin as a radioactive tracer for sentinel lymph node biopsy in breast cancer. Surg Today. 2006;36(3):219-24.
20. Abdollahi A, Jangjoo A, Dabbagh Kakhki VR, Rasoul Zakavi S, Memar B, Naser Forghani M, Mehrabibahar M, Sadeghi R. Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. Rev Esp Med Nucl. 2010 Mar-Apr;29(2):73-7.
21. Dordea M, Colvin H, Cox P, Pujol Nicolas A, Kanakala V, Iwuchukwu O. Clinical and histopathological factors affecting failed sentinel node localization in axillary staging for breast cancer. Surgeon. 2012.
22. Arzoumanian A, Rosenthall L, Seto H. Clinical comparison of 99mTc-labeled preformed phytate colloid and sulfur colloid: concise communication. J Nucl Med. 1977 Feb;18(2):118-20.